Table 1.

Studies characteristics

	Elksniņš-Finogejevs et al.23	Forogh et al.17		Uslu Güvendi et al.18	Huang et al.24	Jubert et al.19
Follow-up period (months)	12	6		6	12	6
Randomized participants, N
PRP	20	24		Single: 19	40	35
				Three: 14
CS	20	24		17	40	30
Analyzed, N
PRP	19	23		Single: 19	40	34
				Three: 14
CS	17	16		17	40	30
Gender, M : F, n
PRP	17 : 03	07 : 17		Single: 1 : 18	21 : 19	12 : 23
				Three: 1 : 13
CS	15 : 05	09 : 15		02 : 15	25:15:00	06 : 24
Age, years, mean/SD or N (%)
PRP	66.4±8.4	59.13±7.03		Single: 62.3±1.6	54.5±1.2	65.56±8.6
				Three: 60.4±1.7
CS	70.2±9.2	61.13±6.7		62.8±1.7	54.3±1.4	68±7.17
BMI, mean/SD or N (%)
PRP	28.6±5.0	28.9±2.8		Single: 31.4±0.7	25.23±4.15	31.20±4.36
				three: 31.0±1.0
CS	30.5±5.8	29.2±3.4		31.0±1.0	24.56±3.62	30.98±4.16
K–L degree, n
PRP	II: 5	II: 7		III	I/II	III: 10
	III: 15	III: 17				IV: 25
CS	II: 6	II: 8		III	I/II	III: 17
	III: 14	III: 16				IV: 13
	Naderi Nabi et al.20	Freire et al.21		Khan et al.25	Nunes-Tamashiro et al.22
Follow-up period (months)	6	6		6	12
Randomized participants, N
PRP	36	25		52	34
CS	36	25		51	33
Analyzed, N
PRP	33	25		52	34
CS	34	25		51	33
Gender, M : F, n
PRP	05 : 28	42 were females		13 : 38	30 : 4
CS	07 : 27			12 : 39	30 : 3
Age, years, mean/SD or N (%)
PRP	59.09±7.79	64.15±8.02		50.912±13.07	67.6 (7.4)
CS	58.55±8.79	60.21±5.92		52.089±12.1	65.8 (6.1)
BMI, mean/SD or N (%)
PRP	28.4±2.78	19 patients were obese, 6 were not		28±4	29.22 (3.2)
CS	27.78±3.29	22 patients were obese, 3 were not		26±5	29.59 (4.5)
K–L degree, n
PRP	I: 9	I: 0	II: 10	II	II: 14
	II: 24	III: 11	IV: 4		III: 20
CS	I: 11	I: 1	II: 10	II	II: 16
	II: 23	III: 14	IV: 0		III: 17

CS, corticosteroid; K–L, Kellgren–Lawrence; PRP, platelet-rich plasma.